Anne L Stephenson1, Kathleen J Ramos2, Jenna Sykes3, Xiayi Ma3, Sanja Stanojevic4, Bradley S Quon5, Bruce C Marshall6, Kristofer Petren6, Joshua S Ostrenga6, Aliza K Fink6, Albert Faro6, Alexander Elbert6, Cecilia Chaparro7, Christopher H Goss8. 1. Department of Respirology, St Michael's Hospital, Toronto, Ontario, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: anne.stephenson@unityhealth.to. 2. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington. 3. Department of Respirology, St Michael's Hospital, Toronto, Ontario, Canada. 4. Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada. 5. Centre for Heart Lung Innovation, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 6. Cystic Fibrosis Foundation, Bethesda, Maryland. 7. Department of Respirology, St Michael's Hospital, Toronto, Ontario, Canada; Toronto Lung Transplant Program, University Health Network, Toronto, Ontario, Canada. 8. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington; Division of Pediatric Pulmonary, Department of Pediatrics, University of Washington Medical Center, Seattle, Washington.
Abstract
BACKGROUND: Previous literature in cystic fibrosis (CF) has shown a 10-year survival gap between Canada and the United States (US). We hypothesized that differential access to and survival after lung transplantation may contribute to the observed gap. The objectives of this study were to compare CF transplant outcomes between Canada and the US and estimate the potential contribution of transplantation to the survival gap. METHODS: Data from the Canadian CF Registry and the US Cystic Fibrosis Foundation Patient Registry supplemented with data from United Network for Organ Sharing were used. The probability of surviving after transplantation between 2005 and 2016 was calculated using the Kaplan‒Meier method. Survival by insurance status at the time of transplantation and transplant center volume in the US were compared with those in Canada using Cox proportional hazard models. Simulations were used to estimate the contribution of transplantation to the survival gap. RESULTS: Between 2005 and 2016, there were 2,653 patients in the US and 470 in Canada who underwent lung transplantation for CF. The 1-, 3-, and 5-year survival rates were 88.3%, 71.8%, and 60.3%, respectively, in the US compared with 90.5%, 79.9%, and 69.7%, respectively, in Canada. Patients in the US were also more likely to die on the waitlist (p < 0.01) than patients in Canada. If the proportion of who underwent transplantation and post-transplant survival in the US were to increase to those observed in Canada, we estimate that the survival gap would decrease from 10.8 years to 7.5 years. CONCLUSIONS: Differences in waitlist mortality and post-transplant survival can explain up to a third of the survival gap observed between the US and Canada.
BACKGROUND: Previous literature in cystic fibrosis (CF) has shown a 10-year survival gap between Canada and the United States (US). We hypothesized that differential access to and survival after lung transplantation may contribute to the observed gap. The objectives of this study were to compare CF transplant outcomes between Canada and the US and estimate the potential contribution of transplantation to the survival gap. METHODS: Data from the Canadian CF Registry and the US Cystic Fibrosis Foundation Patient Registry supplemented with data from United Network for Organ Sharing were used. The probability of surviving after transplantation between 2005 and 2016 was calculated using the Kaplan‒Meier method. Survival by insurance status at the time of transplantation and transplant center volume in the US were compared with those in Canada using Cox proportional hazard models. Simulations were used to estimate the contribution of transplantation to the survival gap. RESULTS: Between 2005 and 2016, there were 2,653 patients in the US and 470 in Canada who underwent lung transplantation for CF. The 1-, 3-, and 5-year survival rates were 88.3%, 71.8%, and 60.3%, respectively, in the US compared with 90.5%, 79.9%, and 69.7%, respectively, in Canada. Patients in the US were also more likely to die on the waitlist (p < 0.01) than patients in Canada. If the proportion of who underwent transplantation and post-transplant survival in the US were to increase to those observed in Canada, we estimate that the survival gap would decrease from 10.8 years to 7.5 years. CONCLUSIONS: Differences in waitlist mortality and post-transplant survival can explain up to a third of the survival gap observed between the US and Canada.
Authors: Anne L Stephenson; Melissa Tom; Yves Berthiaume; Lianne G Singer; Shawn D Aaron; G A Whitmore; Sanja Stanojevic Journal: Eur Respir J Date: 2014-11-13 Impact factor: 16.671
Authors: Marcelo Cypel; Jonathan C Yeung; Mingyao Liu; Masaki Anraku; Fengshi Chen; Wojtek Karolak; Masaaki Sato; Jane Laratta; Sassan Azad; Mindy Madonik; Chung-Wai Chow; Cecilia Chaparro; Michael Hutcheon; Lianne G Singer; Arthur S Slutsky; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz Journal: J Cyst Fibros Date: 2019-03-27 Impact factor: 5.482
Authors: Charles W Hoopes; Jasleen Kukreja; Jeffery Golden; Daniel L Davenport; Enrique Diaz-Guzman; Joseph B Zwischenberger Journal: J Thorac Cardiovasc Surg Date: 2013-01-11 Impact factor: 5.209
Authors: Christian A Merlo; Eric S Weiss; Jonathan B Orens; Marvin C Borja; Marie Diener-West; John V Conte; Ashish S Shah Journal: J Heart Lung Transplant Date: 2009-08 Impact factor: 10.247
Authors: Bradley S Quon; Kevin Psoter; Nicole Mayer-Hamblett; Moira L Aitken; Christopher I Li; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2012-09-13 Impact factor: 21.405
Authors: Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss Journal: Ann Intern Med Date: 2017-03-14 Impact factor: 25.391
Authors: Patricia J Rodriguez; David L Veenstra; Patrick J Heagerty; Christopher H Goss; Kathleen J Ramos; Aasthaa Bansal Journal: Value Health Date: 2021-12-22 Impact factor: 5.101
Authors: Ann L Jennerich; Joseph B Pryor; Travis Y Hee Wai; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos Journal: J Cyst Fibros Date: 2021-12-23 Impact factor: 5.527
Authors: Kathleen J Ramos; Jenna Sykes; Sanja Stanojevic; Xiayi Ma; Joshua S Ostrenga; Aliza Fink; Bradley S Quon; Bruce C Marshall; Albert Faro; Kristofer Petren; Alexander Elbert; Christopher H Goss; Anne L Stephenson Journal: Chest Date: 2021-04-17 Impact factor: 10.262